FDA Approved: VYNDAQEL — Original Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

FDA approved VYNDAQEL (tafamidis meglumine) as the original application for the treatment of transthyretin-related familial amyloid polyneuropathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Amyloid Polyneuropathy
• Transthyretin-mediated Amyloidosis with Polyneuropathy

Drugs mentioned

• Vyndaqel (tafamidis)

Snippet

ORIG AP for VYNDAQEL (TAFAMIDIS MEGLUMINE)